Regeneron and Teva have announced positive top-line phase 3 results from their fasinumab, as the companies chase Pfizer and Lilly in the race to market a new class of non-opioid painkillers.

which are ideal for extracellular targets and those on the cell surface,” said George Yancopoulos, president and chief scientific officer of Regeneron. “Through the RGC and our other research ...

When the GPR75 researh was published, Regeneron's chief scientific officer George Yancopoulos, described the mutations as a "genetic superpower" that "provides hope in combating global health ...

in earlier lines of therapy," said Regeneron's chief scientific officer George Yancopoulos. "We're also excited to be advancing our broader pipeline of CD3 and other bispecific therapies ...

George Yancopoulos. Bain Capital has agreed to buy Mitsubishi Tanabe for around $3.4 bn, setting up one of the largest private equity buyouts in Japan's health sector.

Regeneron hosted a celebration to recognize the achievements of the 17 students selected as the Westchester 2025 Regeneron Science Talent Search Scholars. Beginning in 1942, the contest […] ...

Dr George D. Yancopoulos, Regeneron’s chief scientific officer, said: “We are honoured that the Galien Foundation has recognised Inmazeb […] Our ability to rapidly respond to Ebola was based ...

George D. Yancopoulos, president and chief scientific officer of Regeneron, said: "NASH is a major cause of death in this country, with no current treatment options. We're eager to build on the ...

Yancopoulos, president and chief scientific officer at Regeneron, said in statement. "This latest approval represents an important next chapter for Dupixent, giving those with COPD a novel option ...

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.